KR20240005749A - 뇌경색의 치료에 사용하기 위한 약제학적 조성물 - Google Patents

뇌경색의 치료에 사용하기 위한 약제학적 조성물 Download PDF

Info

Publication number
KR20240005749A
KR20240005749A KR1020237038570A KR20237038570A KR20240005749A KR 20240005749 A KR20240005749 A KR 20240005749A KR 1020237038570 A KR1020237038570 A KR 1020237038570A KR 20237038570 A KR20237038570 A KR 20237038570A KR 20240005749 A KR20240005749 A KR 20240005749A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
cerebral infarction
administered
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237038570A
Other languages
English (en)
Korean (ko)
Inventor
나오코 니시무라
케이지 하스미
카즈오 혼다
Original Assignee
바이오젠 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오젠 엠에이 인코포레이티드 filed Critical 바이오젠 엠에이 인코포레이티드
Publication of KR20240005749A publication Critical patent/KR20240005749A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
KR1020237038570A 2021-05-10 2022-05-10 뇌경색의 치료에 사용하기 위한 약제학적 조성물 Pending KR20240005749A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079820 2021-05-10
JPJP-P-2021-079820 2021-05-10
PCT/US2022/028488 WO2022240810A1 (en) 2021-05-10 2022-05-10 Pharmaceutical composition for use in treating cerebral infarction

Publications (1)

Publication Number Publication Date
KR20240005749A true KR20240005749A (ko) 2024-01-12

Family

ID=82214306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237038570A Pending KR20240005749A (ko) 2021-05-10 2022-05-10 뇌경색의 치료에 사용하기 위한 약제학적 조성물

Country Status (9)

Country Link
US (1) US20240238248A1 (enExample)
EP (1) EP4337193A1 (enExample)
JP (1) JP2024525998A (enExample)
KR (1) KR20240005749A (enExample)
CN (1) CN117295497A (enExample)
AU (1) AU2022275263A1 (enExample)
BR (1) BR112023023534A2 (enExample)
CA (1) CA3216137A1 (enExample)
WO (1) WO2022240810A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7
WO2026092761A1 (zh) * 2024-11-04 2026-05-07 江苏恒瑞医药股份有限公司 包含smtp衍生物的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004224737A (ja) * 2003-01-23 2004-08-12 Ttc:Kk 新規トリプレニルフェノール化合物
JP4313049B2 (ja) 2003-01-23 2009-08-12 株式会社ティーティーシー 血管新生関連疾患の予防又は治療用医薬組成物
KR20080112184A (ko) 2006-03-27 2008-12-24 노우코우다이 티엘오 가부시키가이샤 트리프레닐페놀화합물과 트리프레닐페놀화합물의 제조방법,및 혈전용해촉진제
JP5605659B2 (ja) * 2009-07-06 2014-10-15 国立大学法人東京農工大学 細胞保護剤
JP7381035B2 (ja) * 2018-11-02 2023-11-15 学校法人昭和大学 Ｓｍｔｐ一群又はｓｍｔｐ－７の製造中間体及びその化学的製造方法
CN121064221A (zh) * 2021-02-10 2025-12-05 福建盛迪医药有限公司 一种smtp-7衍生物及其用途
WO2022226013A1 (en) * 2021-04-20 2022-10-27 Biogen Ma Inc. Pharmaceutical composition comprising the compound smtp-7

Also Published As

Publication number Publication date
AU2022275263A1 (en) 2023-11-09
EP4337193A1 (en) 2024-03-20
BR112023023534A2 (pt) 2024-01-30
JP2024525998A (ja) 2024-07-16
US20240238248A1 (en) 2024-07-18
CN117295497A (zh) 2023-12-26
CA3216137A1 (en) 2022-11-17
WO2022240810A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
US20220152053A1 (en) Methods and compositions for treating various disorders
JP6570597B2 (ja) 新規方法
KR20140020912A (ko) 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
US8329693B2 (en) Method for the prevention of thromboembolic disorders
JP2014521658A (ja) ラキニモドおよび酢酸グラチラマーを組み合わせた多発性硬化症の治療
US20140314676A1 (en) Methods of treatment with deferiprone
CA3113376A1 (en) Compositions for reducing serum uric acid
US20240238248A1 (en) Pharmaceutical composition for use in treating cerebral infarction
AU2019354784B2 (en) Biphenyl sulfonamide compounds for the treatment of type IV collagen diseases
TW201247612A (en) Compositions for treating kidney disorders
US20240238252A1 (en) Pharmaceutical composition comprising the compound smtp-7
EP4545072A2 (en) Use of vibegron to treat overactive bladder symptoms in men with benign prostatic hyperplasia
HK40105798A (en) Pharmaceutical composition for use in treating cerebral infarction
JP2006524701A (ja) 酸化防止剤による予防的前処置
Kurosawa et al. A case of an increase in prothrombin Time-International normalized ratio by interaction between warfarin and Baloxavir Marboxil in a patient on implantable ventricular assist device
Seestedt Jr et al. Intracerebral hemorrhage
US9889125B2 (en) Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
HK40105250A (en) Pharmaceutical composition comprising the compound smtp-7
WO2025018279A1 (ja) ヒト移植片対宿主病の治療薬およびその組合せ物
WO2021136549A1 (zh) 马来酸桂哌齐特用于制备防治脑卒中的药物中的应用
CN116832025A (zh) 维拉帕米在制备预防、减轻或延缓椎间盘退变产品中的用途
JP2025525128A (ja) 非経口投与のためのイマチニブ製剤
HK40059411A (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
HK40059411B (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)